Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of temozolomide treatment intensification in adult glioblastoma
2018-000410-38Phase 3Active
- Sponsor
- Centre Oscar Lambret
- Start
- Aug 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Overall survival. Started Aug 2018; status: active.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2018-000410-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000410-38.